CN101678034A - 治疗新血管眼病的方法 - Google Patents

治疗新血管眼病的方法 Download PDF

Info

Publication number
CN101678034A
CN101678034A CN200880010884A CN200880010884A CN101678034A CN 101678034 A CN101678034 A CN 101678034A CN 200880010884 A CN200880010884 A CN 200880010884A CN 200880010884 A CN200880010884 A CN 200880010884A CN 101678034 A CN101678034 A CN 101678034A
Authority
CN
China
Prior art keywords
combination product
patient
vegf
corticosteroid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880010884A
Other languages
English (en)
Chinese (zh)
Inventor
J-P·康宝
E·拉图尔
P·贝利查德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fovea Pharmaceuticals SA
Zalicus Inc
Original Assignee
Fovea Pharmaceuticals SA
CombinatoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals SA, CombinatoRx Inc filed Critical Fovea Pharmaceuticals SA
Publication of CN101678034A publication Critical patent/CN101678034A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880010884A 2007-03-30 2008-03-27 治疗新血管眼病的方法 Pending CN101678034A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07360012.4 2007-03-30
EP07360012 2007-03-30
PCT/EP2008/002426 WO2008119500A1 (en) 2007-03-30 2008-03-27 Methods for treating neovascular ocular diseases

Publications (1)

Publication Number Publication Date
CN101678034A true CN101678034A (zh) 2010-03-24

Family

ID=39564402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880010884A Pending CN101678034A (zh) 2007-03-30 2008-03-27 治疗新血管眼病的方法

Country Status (7)

Country Link
US (1) US20100233194A1 (cg-RX-API-DMAC10.html)
EP (1) EP2139492A1 (cg-RX-API-DMAC10.html)
JP (1) JP2010522774A (cg-RX-API-DMAC10.html)
CN (1) CN101678034A (cg-RX-API-DMAC10.html)
AU (1) AU2008234141A1 (cg-RX-API-DMAC10.html)
CA (1) CA2681361A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008119500A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405301A (zh) * 2015-03-27 2017-11-28 利奥制药有限公司 用于向皮肤递送活性成分的微针贴片

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722015B2 (en) * 2010-04-01 2014-05-13 The Schepens Eye Research Institute, Inc. Compositions and methods for treatment of angiogenesis-associated ocular disorders
WO2011161295A2 (es) * 2010-06-23 2011-12-29 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
ES2970996T3 (es) * 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2006039558A2 (en) 2004-10-09 2006-04-13 Formurex, Inc. Ocular agent delivery systems
US20060148686A1 (en) * 2004-12-30 2006-07-06 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US20070087962A1 (en) * 2005-10-17 2007-04-19 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405301A (zh) * 2015-03-27 2017-11-28 利奥制药有限公司 用于向皮肤递送活性成分的微针贴片
CN107405301B (zh) * 2015-03-27 2021-11-30 利奥制药有限公司 用于向皮肤递送活性成分的微针贴片

Also Published As

Publication number Publication date
EP2139492A1 (en) 2010-01-06
AU2008234141A1 (en) 2008-10-09
JP2010522774A (ja) 2010-07-08
CA2681361A1 (en) 2008-10-09
WO2008119500A1 (en) 2008-10-09
AU2008234141A2 (en) 2009-10-08
US20100233194A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
AU2007247426B2 (en) Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases
JP5706020B2 (ja) 生分解性眼インプラントの製造方法
AU2007334248B2 (en) Devices and methods for ophthalmic drug delivery
EP1755616B1 (en) Treatment of exudative retinopathy with mineralcorticoids
JP2010522774A (ja) 血管新生眼疾患を治療するための方法
CN101820917A (zh) 水性眼科配制剂
US10556008B2 (en) Methods of treatment of keloid using an anti-VEGF agent
CN103402582A (zh) 使用抗水肿疗法治疗黄斑水肿的方法
US20160158320A1 (en) Device and method for the delivery of drugs for the treatment of posterior segment disease
Nentwich et al. The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy
HK1142528A (en) Methods for treating neovascular ocular diseases
Lin et al. IV. E. Principles and Practice of Intravitreal Application of Drugs
AU2005232693B2 (en) Treatment of ophthalmic conditions with mineralcorticoids
HK1132900A (en) Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
Pavesio Intraocular Drug Delivery
Huangb Routes for Drug Delivery: Sustained-Release

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142528

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142528

Country of ref document: HK